EMA begins safety review of ifosfamide cancer medicines
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
List view / Grid view
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
New research has found that there are 362 cell and gene therapies in clinical pipelines in the US, an increase from 2018.
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
A study of over 602 brand-name prescription drugs shows that list prices increased over 1.5 times and net prices rose over 3.5 times inflation in the past decade.
Scientists have developed an innovative nanocarrier that can selectively target and deliver a chemotherapy payload to cancer cells without adverse effects on healthy cells.
Researchers have found that oncology therapies had the most investment in non-industry sponsored clinical trials last year.
Scientists have developed a highly sensitive material that can analyse multiple environmental parameters simultaneously, which could be used in drug delivery.
Over the past decade, the pharmaceutical industry has witnessed rapid growth in outsourcing services, driven by various factors including the growth of small molecules, increasing API complexities and the need to optimise costs. Here, Peter DeYoung shares his thoughts on the key trends he expects to see in the contract…
After clinical trials showed an increased risk of cancer in patients taking Belviq, the FDA has recommended the withdrawal of the drug from the US market.
Oncology, industry-sponsored and a combination of the two, will account for the majority of clinical trials categories over the course of the coming year.
New research from PhRMA found that in the US, there are almost 600 paediatric medicines in development in over 2,000 clinical trials.
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
The first US in-human trial of CRISPR-Cas9-edited T cells has concluded with no ill effects and showed that nine months later the infused cells were still active against cancer.
A report on the protein engineering market suggests it will grow at a CAGR of 12.4 percent, primarily due to protein-based drugs and pharmaceutical company development.